Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonas Saal

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Cancer Research|December 16, 2024
C-Reactive Protein Facilitates Premetastatic Niche Formation in the LungsJonas Saal, Niklas Klümper, Michael Hölzel
European Journal of Cancer (Oxford, England : 1990)|October 25, 2025
Can NaCl predict or even enhance responses to immunotherapy in cancer?Jonas Saal, Michael Hölzel, Niklas Klümper
Journal of Cancer Research and Clinical Oncology|June 22, 2022
Two cases of EBV infection preceding lymphomaJonas Saal, Busher Aboudan, Peter Brossart, et al.
Frontiers in Immunology|October 27, 2025
On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic informationTessa Hattenhauer, Rebekka Mispelbaum, Annkristin Heine, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2024
The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progressionJonas Saal, Markus Eckstein, Manuel Ritter, et al.
Clinical & Translational Immunology|November 10, 2023
Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumorsJonas Saal, Jörg Ellinger, Manuel Ritter, et al.
JNCI Cancer Spectrum|April 2, 2023
Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trialJonas Saal, Tobias Bald, Markus Eckstein, et al.
Lung Cancer (Amsterdam, Netherlands)|February 17, 2024
Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibitionJonas Saal, Tobias Bald, Markus Eckstein, et al.
JAMA Oncology|December 26, 2024
Dissection of Progressive Disease Patterns for a Modified Classification for ImmunotherapyJonas Saal, Markus Eckstein, Manuel Ritter, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2024
High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinomaNiklas Klümper, Alexander Cox, Markus Eckstein, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Cancer Research|December 16, 2024
C-Reactive Protein Facilitates Premetastatic Niche Formation in the LungsJonas Saal, Niklas Klümper, Michael Hölzel
European Journal of Cancer (Oxford, England : 1990)|October 25, 2025
Can NaCl predict or even enhance responses to immunotherapy in cancer?Jonas Saal, Michael Hölzel, Niklas Klümper
Journal of Cancer Research and Clinical Oncology|June 22, 2022
Two cases of EBV infection preceding lymphomaJonas Saal, Busher Aboudan, Peter Brossart, et al.
Frontiers in Immunology|October 27, 2025
On-treatment modified Glasgow Prognostic Score (mGPS) in hepatocellular carcinoma treated with atezolizumab and bevacizumab provides prognostic informationTessa Hattenhauer, Rebekka Mispelbaum, Annkristin Heine, et al.
European Journal of Cancer (Oxford, England : 1990)|December 11, 2024
The modified Glasgow Prognostic Score (mGPS) can guide decisions for immunotherapy treatment beyond progressionJonas Saal, Markus Eckstein, Manuel Ritter, et al.
Clinical & Translational Immunology|November 10, 2023
Pretreatment albumin is a prognostic and predictive biomarker for response to atezolizumab across solid tumorsJonas Saal, Jörg Ellinger, Manuel Ritter, et al.
JNCI Cancer Spectrum|April 2, 2023
Early C-reactive protein kinetics predicts immunotherapy response in non-small cell lung cancer in the phase III OAK trialJonas Saal, Tobias Bald, Markus Eckstein, et al.
Lung Cancer (Amsterdam, Netherlands)|February 17, 2024
Integration of on-treatment modified Glasgow prognostic score (mGPS) to improve imaging-based prediction of outcomes in patients with non-small cell lung cancer on immune checkpoint inhibitionJonas Saal, Tobias Bald, Markus Eckstein, et al.
JAMA Oncology|December 26, 2024
Dissection of Progressive Disease Patterns for a Modified Classification for ImmunotherapyJonas Saal, Markus Eckstein, Manuel Ritter, et al.
European Journal of Cancer (Oxford, England : 1990)|May 4, 2024
High serum sodium predicts immunotherapy response in metastatic renal cell and urothelial carcinomaNiklas Klümper, Alexander Cox, Markus Eckstein, et al.
Pageof 2